| 000 | 01886 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250514214552.0 | ||
| 264 | 0 | _c20050711 | |
| 008 | 200507s 0 0 eng d | ||
| 022 | _a0263-6352 | ||
| 024 | 7 |
_a10.1097/00004872-200502000-00019 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSolini, Anna | |
| 245 | 0 | 0 |
_aEnhanced angiotensin II-mediated effects in fibroblasts of patients with familial hypercholesterolemia. _h[electronic resource] |
| 260 |
_bJournal of hypertension _cFeb 2005 |
||
| 300 |
_a367-74 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAngiotensin II _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aAngiotensin II Type 1 Receptor Blockers _xpharmacology |
| 650 | 0 | 4 |
_aArteriosclerosis _xpathology |
| 650 | 0 | 4 |
_aBiphenyl Compounds _xpharmacology |
| 650 | 0 | 4 |
_aCalcium _xmetabolism |
| 650 | 0 | 4 | _aCase-Control Studies |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 |
_aCholesterol, LDL _xblood |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aEndothelin-1 _xdrug effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFibroblasts _xdrug effects |
| 650 | 0 | 4 | _aHeterozygote |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHyperlipoproteinemia Type II _xblood |
| 650 | 0 | 4 | _aIrbesartan |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMatrix Metalloproteinase 1 _xdrug effects |
| 650 | 0 | 4 |
_aMatrix Metalloproteinase 2 _xdrug effects |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aReceptor, Angiotensin, Type 1 _xmetabolism |
| 650 | 0 | 4 |
_aTetrazoles _xpharmacology |
| 650 | 0 | 4 |
_aTransforming Growth Factor beta _xdrug effects |
| 700 | 1 | _aSantini, Eleonora | |
| 700 | 1 | _aFerrannini, Ele | |
| 773 | 0 |
_tJournal of hypertension _gvol. 23 _gno. 2 _gp. 367-74 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00004872-200502000-00019 _zAvailable from publisher's website |
| 999 |
_c15341091 _d15341091 |
||